Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer

Oncology Letters
Nitin Telang

Abstract

Cancer-initiating stem cells (CISC) represent a minor subpopulation of heterogeneous breast cancer. CISC are responsible for the acquired resistance to conventional chemoendocrine therapy and eventual relapse observed in patients with breast cancer. Certain molecular subtypes of clinical breast cancer that exhibit differential expression of genes coding for hormone and growth factor receptors differ in their response to conventional chemoendocrine therapy and targeted therapeutic inhibitors. Thus, the development of reliable cell culture models for CISC may provide a valuable experimental approach for the study of stem cell-targeted therapy for the treatment of breast cancer. The present study utilized optimized cell culture systems as experimental models for different molecular subtypes of clinical breast cancer, including luminal A, human epidermal growth factor receptor (HER)-2-enriched and triple negative breast cancer. Biomarker end points, including control of homeostatic growth, cancer risk and drug resistance, were quantitatively analyzed in the selected models. The results of the analyses indicated that, compared with the non-tumorigenic controls, the cell models representing the aforementioned molecular subtypes of cl...Continue Reading

References

Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Dec 12, 2003·Nature Reviews. Cancer·Stephen R D Johnston, Mitch Dowsett
Apr 2, 2005·Nature Reviews. Cancer·Michael DeanSusan Bates
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Mar 3, 2007·The Lancet Oncology·Susan CleatorR Charles Coombes
Jul 25, 2007·Annual Review of Cell and Developmental Biology·Neethan A LoboMichael F Clarke
Sep 14, 2007·Nature Reviews. Cancer·John Stingl, Carlos Caldas
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tomonori TaneiShinzaburo Noguchi
Jun 19, 2009·Nature Reviews. Cancer·José Baselga, Sandra M Swain
Aug 25, 2009·Nature Reviews. Cancer·Elizabeth A Musgrove, Robert L Sutherland
Jul 28, 2011·OncoTargets and Therapy·Pham Van PhucPhan Kim Ngoc
Dec 22, 2012·Nature Reviews. Cancer·Jamie N Anastas, Randall T Moon

❮ Previous
Next ❯

Citations

Mar 22, 2018·International Journal of Molecular Sciences·Benjamin B KastenDonald J Buchsbaum
Jan 19, 2018·Oncology Letters·Yu WangZhitu Zhu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis